Differences
This shows you the differences between two versions of the page.
Both sides previous revision Previous revision Next revision | Previous revision | ||
ivci:bordeaux_2025 [2025/05/29 20:41] – [International Summit on Vaccine Coding & Standards] nbunker | ivci:bordeaux_2025 [2025/05/30 08:47] (current) – fkaag | ||
---|---|---|---|
Line 5: | Line 5: | ||
=== Shaping the Future of Global Vaccine Interoperability === | === Shaping the Future of Global Vaccine Interoperability === | ||
- | The first in-person meeting of the International Vaccine Code (IVC) Initiative was held in Bordeaux, bringing together experts from across Europe and North America | + | The first in-person meeting of the International Vaccine Code (IVC) Initiative was held in Bordeaux, bringing together experts from across Europe and Americas |
The meeting opened with a review of IVC's goals and accomplishments so far, including monthly calls, the launch of the IVC website, interviews with countries and organizations, | The meeting opened with a review of IVC's goals and accomplishments so far, including monthly calls, the launch of the IVC website, interviews with countries and organizations, | ||
Line 19: | Line 19: | ||
====== Bordeaux 2025 Meeting Summary ====== | ====== Bordeaux 2025 Meeting Summary ====== | ||
- | **Date:** May 9, 2025 | + | **Date:** May 9, 2025 |
- | **Location: | + | **Location: |
- | **Event:** International Summit on Vaccine Coding & Standards | + | **Event:** International Summit on Vaccine Coding & Standards |
**Hosted by:** International Vaccine Codes Initiative (IVCI) | **Hosted by:** International Vaccine Codes Initiative (IVCI) | ||
Line 43: | Line 43: | ||
===== Session Summaries ===== | ===== Session Summaries ===== | ||
- | === Foundations & Global Perspectives === | + | FOUNDATIONS AND GLOBAL PERSPECTIVES |
==== NUVA: What It Is and Why It Matters ==== | ==== NUVA: What It Is and Why It Matters ==== | ||
Line 52: | Line 52: | ||
- | === Key Takeaways | + | === Key Points |
**Origins and Evolution** | **Origins and Evolution** | ||
Line 94: | Line 94: | ||
A demonstration of the NUVA mapping platform was shared: | A demonstration of the NUVA mapping platform was shared: | ||
- | [https:// | + | [[https:// |
=== Additional Notes === | === Additional Notes === | ||
Line 100: | Line 100: | ||
==== How NUVA Uses Valences to Standardize Vaccine Codes ==== | ==== How NUVA Uses Valences to Standardize Vaccine Codes ==== | ||
- | //Speaker: Jean-Louis Koeck// | + | //Speaker: Jean-Louis Koeck (Syadem)// |
This presentation provided critical clinical context for understanding the valence model at the heart of NUVA. | This presentation provided critical clinical context for understanding the valence model at the heart of NUVA. | ||
- | == Key Takeaways | + | === Key Points === |
* **Core Definitions**: | * **Core Definitions**: | ||
Line 117: | Line 117: | ||
- Vaccine prescription using valence labels rather than commercial product names | - Vaccine prescription using valence labels rather than commercial product names | ||
- | == In Summary == | + | === In Summary |
Valences offer a **common clinical language** to assess protection, regardless of which product or national code system is used. This session made clear that valences are the **core bridge** between vaccination data and actionable immunization guidance. | Valences offer a **common clinical language** to assess protection, regardless of which product or national code system is used. This session made clear that valences are the **core bridge** between vaccination data and actionable immunization guidance. | ||
==== The NUVA Extension to SNOMED CT ==== | ==== The NUVA Extension to SNOMED CT ==== | ||
- | *Speakers: Suzy Roy & Peter Williams (SNOMED International)* | + | //Speakers: Suzy Roy & Peter Williams (SNOMED International)// |
This presentation explained how NUVA is being integrated into the SNOMED CT ecosystem to support broader adoption and interoperability. | This presentation explained how NUVA is being integrated into the SNOMED CT ecosystem to support broader adoption and interoperability. | ||
Line 154: | Line 154: | ||
- | === Real-World Use Cases – Global & European Union === | + | REAL-WORD USE CASES - GLOBAL AND EUROPEAN UNION |
==== EU Strategy for Cross-Border Vaccination Records ==== | ==== EU Strategy for Cross-Border Vaccination Records ==== | ||
- | *Speaker: Georgios Margetidis* | + | //Speaker: Georgios Margetidis, Health and Digital European Agency (HaDEA)// |
- | *Notes | + | |
+ | === Key points === | ||
+ | Georgios presented the frame for the European Commission (EC) actions in the field of digital health. | ||
+ | |||
+ | According | ||
+ | |||
+ | The European Health Data Space (EHDS) regulation, published in March 2025, creates a new context for digital health, with the obligation for Member States to progressively build up interoperability across electronic health records both for primary and secondary use of data. | ||
+ | |||
+ | An harmonized approach for recording administered vaccines would be a significant contribution to this objective. Patient summaries, including vaccination history, should be exchangeable across all Member States by March 2029. | ||
+ | === In summary === | ||
+ | The EHDS regulation allows the EC to become prescriptive on interoperability. | ||
==== View from the Industry (ePIL & NUVA Integration) ==== | ==== View from the Industry (ePIL & NUVA Integration) ==== | ||
Line 216: | Line 226: | ||
- | === Real-World Use Cases – Countries === | + | REAL-WORK USE CASES - COUNTRIES |
==== Luxembourg Experience ==== | ==== Luxembourg Experience ==== | ||
- | //Speaker: Maud Delporte* (Agence eSanté Luxembourg)// | + | //Speaker: Maud Delporte (Agence eSanté Luxembourg)// |
Maud Delporte shared the ongoing efforts in Luxembourg to digitize and centralize vaccine histories through the **Carnet de Vaccination Électronique (CVE)**—a national immunization registry built with NUVA at its core. | Maud Delporte shared the ongoing efforts in Luxembourg to digitize and centralize vaccine histories through the **Carnet de Vaccination Électronique (CVE)**—a national immunization registry built with NUVA at its core. | ||
Line 375: | Line 385: | ||
- | + | IMPLEMENTING | |
- | === Implementing | + | |
==== Mapping Across Code Systems ==== | ==== Mapping Across Code Systems ==== | ||
Line 419: | Line 428: | ||
==== Metrics on Code Systems ==== | ==== Metrics on Code Systems ==== | ||
- | *Speaker: François Kaag (IVCI/ | + | //Speaker: François Kaag (IVCI/ |
François Kaag introduced a method for using NUVA to generate metrics that evaluate the completeness, | François Kaag introduced a method for using NUVA to generate metrics that evaluate the completeness, | ||
- | ==== Key Points | + | === Key Points === |
* **Abstract vs. Concrete Vaccines**: François clarified the terminology around **abstract vaccines**—concepts that describe the vaccine type or valence structure without referring to a branded product. Examples: | * **Abstract vs. Concrete Vaccines**: François clarified the terminology around **abstract vaccines**—concepts that describe the vaccine type or valence structure without referring to a branded product. Examples: | ||
Line 484: | Line 493: | ||
The consensus: IVC should position itself as a collaborative infrastructure partner—bridging multiple organizations working toward better vaccine interoperability. | The consensus: IVC should position itself as a collaborative infrastructure partner—bridging multiple organizations working toward better vaccine interoperability. | ||
- | ===== To Be Added ===== | ||
- | Each section above contains placeholders. Please return and fill in: | ||
- | * Technical and clinical details of each presentation. | ||
- | * Examples or screenshots shown (if any). | ||
- | * Audience questions and feedback from each session. | ||
- | * Any significant quotes or memorable moments from speakers. | ||
Line 496: | Line 499: | ||
- | ==== Slide decks ==== | + | ===== Slide decks ===== |
^ Slides | ^ Slides | ||
| **TRAINING SESSION** | | **TRAINING SESSION** |